S.C.P.C - Interim / Quarterly Report 2023

==> picture [445 x 235] intentionally omitted <==

Standard Chem & Pharm Co., Ltd. Stock Symbol : 1720 2023 Investor Conference 11/16/2023

==> picture [280 x 75] intentionally omitted <==

免責聲明 Safe Harbor Notice

==> picture [88 x 81] intentionally omitted <==

本次簡報與討論包含特定預測性的說明，而其內容有關於營運結果、財務狀況，以及對未來事件的預期。因為此等前瞻性說明是有關於未來事件，而且取決於未來發生時的環境因素，所以必然含有風險與不確定性。

本公司將不負擔公開更新或修改這些預測性的說明之義務，無論是出現新資訊、未來發生任何
事件，或其他情況。實際結果可能與此等預測性說明推測的內容有重大差異。

In these presentations and discussions, there are certain forward looking statements regarding the results of operation, financial condition and current expectation about future events. As forward-looking statements relate to events and depend on circumstances in the future, they involve risk and uncertainty.

We do not undertake any obligation to publicly revise or update any forward looking statements for availability of new information, future events or otherwise. Real result probably differ substantially from those expected in these forward-looking statements.

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2023 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

 Introduction of Standard Group

 2023 Q1-Q3 Operating Results

 Future Operation Strategy  Corporate Social Responsibility (CSR)

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2023 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

 Introduction of Standard Group

 2023 Q1-Q3 Operating Results  Future Operation Strategy  Corporate Social Responsibility (CSR)

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

3
----- End of picture text -----

==> picture [842 x 475] intentionally omitted <==

----- Start of picture text -----

SCP and Related/Affiliated Com nies
pa
Upstream Manufacture Channels
Syn-Tech (1982; 2005
SCP(1967;
Taiwan Biosim(2017)
Over-The-Counter (OTC))
Western 1995 listed stock)
medicine
Your Chance
Syngen(1999; 2016 OTC) Souriree(1997)
(Invested in 2013;
2022 Pioneer Stock Board (PSB))
Syngen(1999)
Healthcare Multipower
nutrition (Invested in 2012)
Sun-you(1994)
Medical- Syngen (1999)
devices
Q
Ho Yao Biopharm (2021)
Obtained CRO certification In October 2023
4
© 2023 SCP, Ltd
----- End of picture text -----

International Accreditation

==> picture [606 x 32] intentionally omitted <==

----- Start of picture text -----

1998 2000 2008 2009 2010 2017 2021
----- End of picture text -----

==> picture [42 x 45] intentionally omitted <==

==> picture [29 x 38] intentionally omitted <==

The first TW pharmaceutical company to be ISO9001 certified

==> picture [50 x 32] intentionally omitted <==

==> picture [46 x 25] intentionally omitted <==

The first TW company to pass US FDA inspection in 2000

Subsequent US FDA GMP inspections : no 483 Last Inspection : 2022/10/31

==> picture [28 x 37] intentionally omitted <==

SCP received JP PMDA’s “Certificate of Foreign Drug Manufacturer” in 2008

FDF Plant and API Plant passed PMDA GMP Audit in 2018

==> picture [50 x 31] intentionally omitted <==

==> picture [58 x 37] intentionally omitted <==

2009

==> picture [48 x 33] intentionally omitted <==

SCP’s API plant passed AU TGA inspection

==> picture [44 x 34] intentionally omitted <==

==> picture [48 x 36] intentionally omitted <==

2010 SCP passed TW PIC/S GMP inspection 2012 SCP is certified GDP by the T-FDA

==> picture [49 x 33] intentionally omitted <==

==> picture [70 x 31] intentionally omitted <==

2012 SCP passed K-FDA inspection

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2023 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

 Introduction of Standard Group

 2023 Q1-Q3 Operating Results

 Future Operation Strategy  Corporate Social Responsibility (CSR)

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

6
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Consolidated Income Statement

Items	2023 Q1-Q3	2022 Q1-Q3	Diff.	Annual changes (%)
(Unless otherwise specified, expressed in thousands of New Taiwan Dollars)
Operating revenue	4,647,560	4,268,103	379,457	8.9%
Gross profit	2,035,285	1,805,887	229,398	12.7%
Gross profit margin	43.79%	42.31%		1.48pct
Operating expenses	1,082,817	991,207	91,610	9.2%
Operating profit	952,468	814,680	137,788	16.9%
Non-operating income and expenses	223,387	317,843	(94,456)	(29.7%)
Profit before income tax	1,175,855	1,132,523	43,332	3.8%
Profit for the year	947,469	927,154	20,315	2.2%
Profit attributable to Shareholders of the parent	673,176	640,506	32,670	5.1%
EPS(NTD)	3.77	3.58	0.19	5.3%
2023 SCP, Ltd

Comparison of Quarterly Revenue of Past 5 Years (Consolidated)

Expressed in thousands of NTD

0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2019 2020 2021 2022 2023 19 20 21 22 23 19 20 21 22 23 19 20 21 22 19 20 21 22 23	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2019 2020 2021 2022 2023 19 20 21 22 23 19 20 21 22 23 19 20 21 22 19 20 21 22 23	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2019 2020 2021 2022 2023 19 20 21 22 23 19 20 21 22 23 19 20 21 22 19 20 21 22 23	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2019 2020 2021 2022 2023 19 20 21 22 23 19 20 21 22 23 19 20 21 22 19 20 21 22 23	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2019 2020 2021 2022 2023 19 20 21 22 23 19 20 21 22 23 19 20 21 22 19 20 21 22 23	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2019 2020 2021 2022 2023 19 20 21 22 23 19 20 21 22 23 19 20 21 22 19 20 21 22 23	0 200,000 400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 Q1 Q2 Q3 Q4 2019 2020 2021 2022 2023 19 20 21 22 23 19 20 21 22 23 19 20 21 22 19 20 21 22 23
	Q1	Q2	Q3	Q4	Total	Growth(%)
2019	846,177	1,010,837	1,048,886	1,031,229	3,937,129	+10.2%
2020	1,034,417	1,108,059	1,045,351	1,117,573	4,305,400	+9.4%
2021	1,101,113	1,149,060	1,120,840	1,233,069	4,604,082	+6.9%
2022	1,237,170	1,481,061	1,549,872	1,583,265	5,851,368	+27.1%
2023	1,493,025	1,509,004	1,645,531		4,647,560	+8.9%

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Consolidated Balance Sheet

Items	2023/09/30	2023/09/30	2022/09/30	2022/09/30	Diff.	Annual changes(%)
(Expressed in thousands of NTD)	Amount	%	Amount	%
Cash and cash equivalents	1,956,260	17.9%	2,454,867	22.0%	(498,607)	(20.3%)
Accounts receivable	1,445,772	13.2%	1,424,976	12.8%	20,796	1.5%
Inventories	1,520,828	13.9%	1,322,473	11.8%	198,355	15.0%
Investments	1,099,750	10.0%	1,464,606	13.1%	(364,856)	(24.9%)
Property,plant and equipment	4,004,833	36.6%	3,529,686	31.6%	475,147	13.5%
Others	926,081	8.5%	971,562	8.7%	(45,481)	(4.7%)
Total Assets	10,953,524	100.0%	11,168,170	100.0%	(214,646)	(1.9%)
Current Liabilities	2,535,532	23.1%	3,306,926	29.6%	(771,394)	(23.3%)
Non-current Liabilities	591,278	5.4%	700,316	6.3%	(109,038)	(15.6%)
Total liabilities	3,126,810	28.5%	4,007,242	35.9%	(880,432)	(22.0%)
Total shareholder’s equity	7,826,714	71.5%	7,160,928	64.1%	665,786	9.3%
Debt Ratio(Liabilities/Assets)		28.5%		35.9%
2023 SCP, Ltd

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Consolidated Cash Flows

==> picture [88 x 81] intentionally omitted <==

Items	2023 Q1-Q3	2022 Q1-Q3
(Expressed in thousands of NTD)
Cash at beginning ofyear	2,259,381	2,564,395
Cash flows from operatingactivities	910,300	962,804
Acquisition ofproperty, plant and equipment	(488,791)	(1,012,966)
Cash dividends	(446,740)	(446,740)
Short & long-term borrowings	(230,713)	699,183
Investment and others	(47,177)	(311,809)
Cash at end ofyear	1,956,260	2,454,867

Free cash flow (Cash flows from operating activities-Acquisition of property, plant and equipment)	421,509	(50,162)

1720 SCP achieved a record high net profit after tax and EPS in 2023 Q1-Q3

NTD Thousand

==> picture [644 x 349] intentionally omitted <==

----- Start of picture text -----

稅後淨利現金股利股票股利 EPS
900,000 5.00
4.56
800,000 4.50
3.95
3.77
4.00
700,000
3.50
600,000 2.93
3.00
500,000
400,000 2.09 [2.15 ] 2.09 1.95 1.90 2.03 2.09 2.11 2.50
1.77 [1.81 1.88 ]
2.00
300,000 1.35 [1.47 1.61 1.73 ]
1.50
2.50
2.50
200,000 1.20 [1.50] [1.25] 1.20 [1.60] 0.50 1.00 1.20 1.00 1.50 1.50 1.60 1.50 1.50 [1.80] 1.00
100,000 0.50
2.50
0.30 0.30 0.70
0 0.00
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

1777 SYN-TECH’s net profit after tax and EPS - in 2023 Q1 Q3

NTD Thousand

==> picture [647 x 361] intentionally omitted <==

----- Start of picture text -----

稅後淨利現金股利股票股利 EPS
350,000 9
8
300,000
6.62
7
6.21
250,000
5.03 6
5.06
5.12 [5.31 ]
4.93 [5.20 5.27 ]
200,000 5
150,000 3.33 3.38 4
3.10
2.93
2.37 2.15 3
100,000 1.74 2.19 1.89 3.00
1.00 3.50 [3.50] 3.30 [3.50] [4.00] 2
1.99
50,000 2.00 [2.40] 1.30 1.93 [3.00]
1.75 1
1.70 1.52 [1.00] [2.30] 2.00
0.50
0 0
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

8279 Syngen’s net profit after tax and EPS in 2023 Q1-Q3

NTD Thousand

==> picture [668 x 355] intentionally omitted <==

----- Start of picture text -----

稅後淨利現金股利股票股利 EPS
400,000 14.00
11.85
350,000
12.00
300,000
10.00
8.77
250,000 7.86 7.95 8.04
8.00
6.43
200,000
5.8
6.00
4.69
150,000
3.76
4.00
100,000 3.50
2.04 4.00
2.00
50,000 1.00 1.00
2.50
0.50 3.00 5.00
0.00 1.00
0 0.00
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

13
----- End of picture text -----

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2023 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

 Introduction of Standard Group  2023 Q1-Q3 Operating Results

 Future Operation Strategy  Corporate Social Responsibility (CSR)

Future Milestone

==> picture [697 x 88] intentionally omitted <==

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

15
----- End of picture text -----

Significant Business Activities in the Past Two Years


Taiwan	China	Japan
• Double-digit growth in	• Strategy: cooperation	• Continues shipments
clinic and hospital. • Southeast Asia region’s sales growth. • Establishment of marketing team for Philippines subsidiary. • Record-high revenue and profits in the first	through technology transfer and import our own branded products. • Consistency Evaluation(GQCE):3 reviews in progress. • Under R&D:5cases.	of medications for bronchiolitis and oral anti-inflammatory and pain relief medications. • CDMO contract signed for development of medication for pulmonary arterial hypertension.
three quarters by 2023.		• Acting as importer for new medicines, with a
		submission scheduled
		for 2023 and expected market launch in 2025.
2023 SCP Ltd

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Revenue Growth Strate -Taiwan gy

==> picture [127 x 181] intentionally omitted <==

SCP (1720) 3.77 S n-Tech 1777 5.06 y ( ) S n en 8279 8.04 y g ( )

 Outstanding performance

Specializing in four key areas:
Western medicines, APIs, health supplements, and pharmaceutical chain stores.
SCP, Syn-Tech, Syngen, and Your Chance boast exceptional management teams

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

17
----- End of picture text -----

China Market Trends: Current

The release of policies such as the '14th Five-Year Plan for the Development of the Pharmaceutical Industry' and the '14th Five-Year Plan for National Drug Safety and the Promotion of High-Quality Development' signifies the coexistence of opportunities and challenges in the pharmaceutical industry. It aims to advance towards international high-end standards while ensuring drug safety, promoting the high-quality development of the pharmaceutical industry, and safeguarding and enhancing public health.

National industry Government policy support

Aging population Income growth

In 2010, 8.87% of the population was aged 65 or older. By 2022, this had risen to 14.9%, indicating an aging society with growing healthcare needs. In the first half of 2023, the average resident income increased by 6.5% to RMB19,672, contributing to the continuous growth of the healthcare industry due to higher income and healthcare expenditure.

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

China Market Trends: Current

New Regulations In 2018, the Health Insurance Bureau was established, introducing changes in drug procurement, healthcare negotiations, and the for Healthcare essential drug list. Concerns about drug price stability arose in the capital market. Negotiations The release of the "2022 National Drug List Adjustment Program" and Reduced related regulations reduced the risk of renegotiating contracts for drugs Uncertainty and on the list every two years. It also expanded coverage to include Risks pediatric and rare disease medications, incorporating more drugs into

The release of the "2022 National Drug List Adjustment Program" and related regulations reduced the risk of renegotiating contracts for drugs on the list every two years. It also expanded coverage to include pediatric and rare disease medications, incorporating more drugs into the national health insurance system.

In 2022, large pharmaceutical firms had revenue growth but declining profits. Small companies like Jingxin Pharmaceutical, Salubris, and Haisco Pharmaceutical overcame procurement challenges. Early-stage biotech companies outpaced mature pharmaceutical firms in revenue growth.

Pandemic Impact Gradual Recovery

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

19
----- End of picture text -----

==> picture [811 x 474] intentionally omitted <==

----- Start of picture text -----

China Market Trends: Current
•
In mid-December 2022, China ended its "zero-COVID" policy, causing a rebound in
pharmaceutical sales. By 2023, overall sales for hospitals and pharmacies were
gradually stabilizing.
(Unit: Hundred million/RMB)
16000 Hospital Drugstore Overall sales
14063
13782 13664
14000 13313
12931
12000
10984
10386 10465 10298
9715
10000
8000 7378
6000 5558
Q
4000 2927 3079 3216 3317 3366
1820
2000 Source：
www.menet.com.cn
20
China (public hospital and
0 b rick-and-mortar
© 2023 SCP, Ltd 2018 2019 2020 2021 2022 2023 H1 pharmacy)
----- End of picture text -----

Revenue Growth Strate - China gy

==> picture [88 x 81] intentionally omitted <==

==> picture [67 x 54] intentionally omitted <==

==> picture [71 x 73] intentionally omitted <==

==> picture [72 x 71] intentionally omitted <==

Competitiveness

Project initiation/Research Achievements

==> picture [16 x 15] intentionally omitted <==

SCP has successful experience with U.S. and Japan regulatory dossiers
5 ongoing cases NMPA Consistency Evaluation
Expertise in Fasting & Fed BE design and execution

==> picture [57 x 57] intentionally omitted <==

==> picture [70 x 68] intentionally omitted <==

Medium-term targets
Self-developed products submission
3 cases submitted for evaluation
2 cases obtained the consistency evaluation

==> picture [57 x 57] intentionally omitted <==

Enhance profit sharing revenue

Cooperation

Strategy

Tech-transfer
Emphasize export and tech transfer simultaneously
Joint ownership of License
Cooperative production and marketing
Accelerate license acquisition to become MAH

Q

Profit-sharing Partnerships
Expand the number of collaborative projects and pharmaceutical companies

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

21
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Ja an Market Trend p

Inadequate supply of generic drugs has been a persistent problem. Some pharmaceutical companies stopped shipments due to quality issues, causing shortages. Increasing production is difficult, and it may take time to resume normal supply.

==> picture [6 x 32] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [6 x 31] intentionally omitted <==

Joint development trend is slowing, with around 50% of newly licensed items in 2022 being joint ventures

==> picture [57 x 57] intentionally omitted <==

2022 Drug shortage and controlled shipment

==> picture [435 x 174] intentionally omitted <==

----- Start of picture text -----

Shortages Controlled shipment
Category
Num# % Num# %
Brand 52 4.6% 248 7.9%
Generic 997 90.7% 2811 89.7%
Q
Other 50 4.6% 76 2.4%
Total 1099 100% 3135 100%
----- End of picture text -----

==> picture [6 x 32] intentionally omitted <==

－ Current Japan Market Anal sis of Generic Dru Manufacturers' Production Ca acit y g p y

Roughly 30 generic drug manufacturers produce over 100 items annually, making up 16% of all generic drug makers. About 24 of them have an annual production capacity exceeding 1 billion (tablets/injections combined).

Over 10 billion (tablets/injections) 1 million to 10 billion (tablets/injections) 100 million to 1 billion (tablets/injections) 10 to 100 million (tablets/injections) 1 to 10 10 million (tablets/injections) Under 1 million

> 500 items: 3 companies

Between 100 to 499 items: 27 companies

Between 50 to 99 items: 10 companies

<50 items: 148 companies

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

－ Current Japan Market Production is concentrated in a few lar e-scale manufacturers g

Out of 193 generic drug manufacturers, the top 8 companies account for 50% of the total production quantity

==> picture [16 x 15] intentionally omitted <==

==> picture [507 x 332] intentionally omitted <==

----- Start of picture text -----

Production quantity of the top 8
companies accounts for 50% of
the total generic drug production
Most companies produce
relatively small quantities
© 2023 SCP, Ltd
----- End of picture text -----

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

24
----- End of picture text -----

Revenue Growth Strate - Ja an gy p

==> picture [71 x 63] intentionally omitted <==

==> picture [67 x 64] intentionally omitted <==

Strategy

Collaboration Model

Agent for brand new drugs.
CDMO
Collaborating with Japan pharmaceutical company to enter other markets.
Japan marketing partner
Strategic alliance with API manufacturer.
API Vertical Integration with Syn-Tech.
Self-owned license

==> picture [69 x 65] intentionally omitted <==

----- Start of picture text -----

•
----- End of picture text -----

Current State

On Going

Obtained two CDMO/CMO collaborations for generic drug products.
CDMO/CMO
Common items for China/ Southeast Asia/ Japan are under discussion
Acting as an agent for a new gout medication, registration is in progress.
Signed a CDMO development collaboration contract for pulmonary arterial hypertension products.

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [88 x 81] intentionally omitted <==

US Market Trend

In the 2022 U.S. market, generic drugs constituted 90% of sales volume but only 17.5% of sales value.

==> picture [57 x 57] intentionally omitted <==

They represent less than one-fifth of pharmaceutical spending in the U.S.

Sales Volume ratio

US Healthcare Expenditure

==> picture [352 x 251] intentionally omitted <==

----- Start of picture text -----

100%
90%
80%
70%
60%
89.9% 89.9% 90.2% 90.2% 90.3%
50%
40%
30%
20%
10%
10.2% 10.1% 9.8% 9.8% 9.4% 9.7%
0%
2017 2018 2019 2020 2021 2022
----- End of picture text -----

==> picture [396 x 236] intentionally omitted <==

----- Start of picture text -----

7.90%
1.50% Q
----- End of picture text -----

==> picture [36 x 236] intentionally omitted <==

==> picture [228 x 31] intentionally omitted <==

==> picture [8 x 8] intentionally omitted <==

==> picture [9 x 8] intentionally omitted <==

US – Generic Drug Competition and Price Relationshi Chart p

Data from the FDA indicates that as more competitors enter the market, the price difference between pharmacy invoices and average manufacturer prices decreases, and generic drug prices become more affordable compared to brand-name drugs.

==> picture [6 x 31] intentionally omitted <==

==> picture [461 x 314] intentionally omitted <==

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

27
----- End of picture text -----

Revenue Growth Strate – U.S.A. gy

==> picture [154 x 110] intentionally omitted <==

U.S.A. Market

Largest Rx Market, with large proportion of generic drugs.
Application process for drug licenses is complex, costly, and requires long-term planning

==> picture [54 x 54] intentionally omitted <==

Current Status

Strategy

Co-develop new
Uninterrupted factory inspections success since 2000.
products with pharmaceutical companies and dealers.
Products for diabetes and ALS have been shipped.
API Vertical Integration with Syn-Tech.
P4 product set to launch in 2023."
Seeking Early Market Entry for First to File.

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

28
----- End of picture text -----

Future Operation Strategy

Future From Taiwan to International From Generics to BTG

2024 2023 、、 USA Japan

、 China Japan

Core techniques and Increasing oversea professional Oversea marketing Resource proportion 增加海核心技術 skills to expend & 專業海外市場操作 practices oversea sales 借力使力 • 外比例 • • Increase resources for Use mature Taiwanese Establish a solid foundation. overseas business.

Use mature Taiwanese technology to create R&D wealth.
Quickly generate revenue.
Recruit and train international talents.
Learn the rules of the game. in various markets.
Jointly plan and operate in various markets. markets with foreign • Seek for long-term partners.
companies.

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

29
----- End of picture text -----

==> picture [229 x 475] intentionally omitted <==

==> picture [88 x 81] intentionally omitted <==

Agenda

 Introduction of Standard Group  2023 Q1-Q3 Operating Results  Future Operation Strategy

 Corporate Social Responsibility (CSR)

Fan Dao Nan Foundation

==> picture [156 x 115] intentionally omitted <==

Introduction to the foundation

Established in 1987
Endowment Fund: NT$196 Million
Annual Budget: NT$12 Million

==> picture [157 x 113] intentionally omitted <==

Principal Activities

Cultural and educational development activities
Public education affairs
Children’s education and happiness
Scholarships and Talent Cultivation

==> picture [158 x 114] intentionally omitted <==

Rewards and Honors Received

2011: Special Recognition Award – Ministry of Education
2012: Tainan City Govt. Grant for Scholarship Program
2013: National Special Selection Award for
After-School Program – Dept. of Education
2022: Group Award on Social Education Contribution by Ministry Of Education

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [807 x 474] intentionally omitted <==

----- Start of picture text -----

2023 Corporate Social Responsibility
Scholarships
Hope After-school Class Sunflower Wednesdays
 Pharmaceutical or related major: 1
universities/ 2 students •Weekday afternoons •Every Wednesday afternoons
High school :5 schools, totaled 91 students
Middle school:53 schools, totaled 687 students •33 schools，2,315 students •9 Schools，550 students
 Elementary school: 219 schools, totaled 2,602
students
NTD 5.50 million NTD 1.00 million NTD 0.20 million
Other Sponsorships Meal-Assistance
Charity
 organizations.Sponsor 12 public welfare  Provided 8,280 meals  SCP Children’s Drawing Competition
NTD0.60 million
 SCP National Table Tennis Q
Competition NTD1.80 million
NTD 0.60 million NTD 0.61 million NTD 2.40 million
32
2023 SCP, Ltd
----- End of picture text -----

Donation of disaster assessment vehicles in 2023

==> picture [594 x 385] intentionally omitted <==

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Senior Gym in Taiwan – Athletic Trainin and Health Center g

==> picture [88 x 81] intentionally omitted <==

==> picture [317 x 238] intentionally omitted <==

==> picture [313 x 234] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [392 x 199] intentionally omitted <==

----- Start of picture text -----

Q
34
----- End of picture text -----

Jan. to Oct. 2023,

Accumulated a total of 125,773 user times.
Held 17 health and wellness seminars and fitness courses

==> picture [236 x 475] intentionally omitted <==

Q & A

==> picture [88 x 81] intentionally omitted <==

AI assistant

S.C.P.C — Interim / Quarterly Report 2023

51900_rns_2023-11-15_d0ec3948-ae3d-409f-a0d9-a60b91b9d89a.pdf

免責聲明 Safe Harbor Notice

Agenda

Agenda

International Accreditation

Agenda

Consolidated Income Statement

Comparison of Quarterly Revenue of Past 5 Years (Consolidated)

Expressed in thousands of NTD

Consolidated Balance Sheet

Consolidated Cash Flows

1720 SCP achieved a record high net profit after tax and EPS in 2023 Q1-Q3

NTD Thousand

1777 SYN-TECH’s net profit after tax and EPS - in 2023 Q1 Q3

NTD Thousand

8279 Syngen’s net profit after tax and EPS in 2023 Q1-Q3

NTD Thousand

Agenda

Future Milestone

Significant Business Activities in the Past Two Years

Revenue Growth Strate -Taiwan gy

China Market Trends: Current

Aging population Income growth

China Market Trends: Current

Revenue Growth Strate - China gy

Competitiveness

Project initiation/Research Achievements

Cooperation

Strategy

Q

Ja an Market Trend p

2022 Drug shortage and controlled shipment

－ Current Japan Market Anal sis of Generic Dru Manufacturers' Production Ca acit y g p y

－ Current Japan Market Production is concentrated in a few lar e-scale manufacturers g

Revenue Growth Strate - Ja an gy p

Strategy

Collaboration Model

Current State

On Going

US Market Trend

Sales Volume ratio

US Healthcare Expenditure

US – Generic Drug Competition and Price Relationshi Chart p

Revenue Growth Strate – U.S.A. gy

U.S.A. Market

Current Status

Strategy

Future Operation Strategy

Agenda

Fan Dao Nan Foundation

Introduction to the foundation

Principal Activities

Rewards and Honors Received

Donation of disaster assessment vehicles in 2023

Senior Gym in Taiwan – Athletic Trainin and Health Center g

Jan. to Oct. 2023,

Q & A

More from S.C.P.C

S.C.P.C Interim / Quarterly Report 2023